Archive · 25 Jul 2025
Cipla Q1 FY26 Results: Strong Financial Performance
Cipla, a pharmaceutical company, had a good start to its financial year.
They made more money compared to last year.
Their profits also went up, and they managed their costs well, keeping their profit margin steady.
The company's business in India did very well, reaching its highest point ever for that time of year.
Cipla also performed well in Africa and had a steady performance in North America.
They have a lot of cash and are investing in research to create new medicines.
Cipla's income from operations increased by 4% year-on-year to Rs 6,957 crore in Q1 FY26.
Profit after tax (PAT) rose 10% year-on-year to Rs 1,298 crore.
EBITDA margin remained steady at 25.6%, indicating strong cost controls and operational efficiency.
India business achieved a record high, crossing Rs 3,000 crore for the first time in Q1.
The company has a strong cash balance of Rs 10,379 crore as of June 2025.
- Who
- Cipla, a pharmaceutical company.
- What
- Cipla announced its Q1 FY26 financial results.
- When
- Q1 FY26 (period unspecified, assumed to be ending June 2025 based on cash balance date).
- Where
- Across various markets including India, North America, Africa, and Europe.
- Why
- To report on financial performance, including revenue, profit, and key business segment results.
- Income from Operations
- Rs 6,957 crore (Q1 FY26)
- PAT (Profit After Tax)
- Rs 1,298 crore (10% YoY growth)
- EBITDA Margin
- 25.6%
- India Business Revenue
- Rs 3,070 crore (Q1, highest ever)
- North America Revenue
- USD 226 million
- R&D Investments
- Rs 432 crore (6.2% of sales)
- Net Cash Balance
- Rs 10,379 crore (June 2025)